Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NexgenRxNEGXF 46 Graham Number is $0.14 as of Mar. 2026, which is 95% below its 10-year median of 3.08. GuruFocus rates NEGXF with a GF Score™ of 46/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 368 Healthcare Providers & Services companies, NexgenRx ranks worse than 76.9% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-08-05), the stock price of NexgenRx is $0.325. NexgenRx's graham number for the quarter that ended in Mar. 2026 was $0.14. Therefore, NexgenRx's Price to Graham Number ratio for today is 2.28.
The historical rank and industry rank for NexgenRx's Graham Number or its related term are showing as below:
NEGXF'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.65 Med: 3.08 Max: 12
Current: 3.61
During the past 13 years, the highest Price to Graham Number ratio of NexgenRx was 12.00. The lowest was 1.65. And the median was 3.08.
NEGXF's Price-to-Graham-Number is ranked worse than 76.9% of 368
companies
in the Healthcare Providers & Services industry
Industry Median: 1.65
vs NEGXF: 3.61
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
NexgenRx's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
0.325
/
0.14
=
2.28
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
NexgenRx Graham Number Related Terms
NexgenRx Graham Number Historical Data
* Premium members only.
The historical data trend for NexgenRx's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NEGXF vs VEEV, BTSG, HQY: Graham Number Comparison
For the Health Information Services subindustry, NexgenRx's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexgenRx Price-to-Graham-Number vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where NexgenRx's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexgenRx (NEGXF) has a Graham Number of $0.14 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on NexgenRx and its competitors. This is 95% below median its historical median of 3.08. Over the past decade, NexgenRx's Graham Number has ranged from 1.65 to 12.00. According to the industry distribution chart, NexgenRx ranks #283 out of 368 companies in the Healthcare Providers & Services industry, placing it in the top 76.9%.
Is NexgenRx's Graham Number too high?
NexgenRx's current Graham Number of $0.14 is 95% below median its 10-year median of 3.08. Over the past 10 years, this metric has ranged from a low of 1.65 to a high of 12.00. The Healthcare Providers & Services industry median Graham Number is 1.65. NexgenRx's value of $0.14 is 91.5% below this industry median. Based on the distribution chart, NexgenRx ranks #283 out of 368 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, NexgenRx has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's Graham Number compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #283 out of 368 companies for Graham Number. This places NexgenRx in the lower half of its industry. The industry median Graham Number is 1.65. NexgenRx's value of $0.14 is 91.5% below this benchmark. Historically, NexgenRx's own Graham Number has ranged from 1.65 to 12.00 over the past decade. While the company's 10-year median is 3.08 vs. the industry median of 1.65, NexgenRx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Healthcare Providers & Services company?
The median Graham Number among Healthcare Providers & Services companies is 1.65, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NexgenRx's current Graham Number of $0.14 is 91.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on NexgenRx and its competitors. For the Healthcare Providers & Services industry, the median Graham Number is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current Graham Number is $0.14, which is 95% below median its own 10-year median of 3.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.33 — trading 20.4% above its estimated fair value. The current Graham Number is $0.14, which is 95% below median its 10-year median of 3.08 and 91.5% below the Healthcare Providers & Services industry median of 1.65. NexgenRx's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For NexgenRx (NEGXF), the current Graham Number is $0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (NEGXF) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27.
GuruFocus considers NexgenRx to be Modestly Overvalued.
Key valuation signals for NEGXF:
Graham Number: $0.14 (95% below median its 10-year median of 3.08)
GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
Industry Position: 91.5% below the Healthcare Providers & Services median (#283 of 368)
No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
46GF Score
Get the complete analysis for NEGXF
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEGXF has been successfully added to your 
